The website is launched on 29 June 2018

Combined hormonal contraception

Long term safety of hormonal contraception

Contraceptives and breast cancer: recent updates

More than 100,000 women
More than 1 million women years
Present use: RR 1.33 (C.I. 1.03-1.73) only due to triphasic LNG
Past use: RR 1.12 (C.I. 0.95-1.33)

Hunter et al. Cancer Epidemiol Biomarkers Prev 19: 2496-2502, 2010

Compared with “ever users”, “never users” of OC had a significantly LOWER incidence from any cause (adjusted RR 0.86, CI 0.82-0.93, n=46112 (378006 and 819175 WY, respectively)

Hannaford et al, BMJ, 2010:346

Combined hormonal contraception

Protection from some cancers e.g. endometrial and ovarian cancers, up to 50% risk reduction

Protection against benign diseases e.g. benign breast diseases like fibrocystic and fibroadenomatosis disease decreased by 50-70%

Other possible health benefits

  • Protection against pelvic inflammatory diseases
  • Reduces risk of follicular cyst by 50% and corpus luteal cyst by 80%
  • Past contraceptive use protects women after they reach menopause; reduced risk of low bone mineral density was documented
  • Reduction in acne

ESHRE Capri Workshop Group. Hum Reprod Update 11:513-525, 2005

Disclaimer: The information contained in this website is for general information purposes only. The information is provided by MMA Online Contraceptive Course and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.